Tai-Chong Announces Board Approval of Exclusive Licensing Agreement with Subsidiary TCM Life Science Inc. for U101

1. Date of Event: 115/07/02 2. Contracting Party: TCM Life Science Inc. 3. Relationship with the Company: TCM Life Science Inc. is a U.S.-based subsidiary wholly owned (100%) by the Company. 4. Contract Period (or Termination Date): The agreement becomes effective upon receipt of funding or sublicense revenue by TCM Life Science Inc., as stipulated in the contract. The licensing term shall last for the duration of the patent's validity or ten years post-approval in each region, whichever is longer. 5. Main Content (Not applicable for termination): The Company grants an exclusive license for U101 to its U.S. subsidiary, TCM Life Science Inc., enabling it to conduct global clinical development, regulatory registration, manufacturing, and commercialization. The total contract value, including development and sales milestone payments, is USD 750 million. 6. Restrictive Clauses (Not applicable for termination): As specified in the contract. 7. Commitments (Not applicable for termination): As specified in the contract. 8. Other Important Agreements (Not applicable for termination): As specified in the contract. 9. Impact on Company's Financials and Operations: This agreement will facilitate the international expansion of U101. 10. Specific Purpose: To authorize the U.S. subsidiary to conduct global R&D (including Phase III clinical trials) and commercialization of U101 in global markets. 11. Other Matters to be Disclosed: This announcement constitutes a material event under Article 7, Clause 8 of the Enforcement Rules of the Securities and Exchange Act, as it significantly impacts shareholder equity or stock price. The Board authorizes the Chairman to handle all related matters, sign documents, and complete necessary procedures as required.